We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$725M
Cap. Flow %
-39.12%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 6.29%
2 Materials 0.25%
3 Financials 0.16%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EDIT icon
101
CALL
Editas Medicine
EDIT
$399M
$1.75M 0.09%
+784
New +$16.2K
DRRX
102
DELISTED
DURECT Corp
DRRX
$1.74M 0.09%
165,961
+13,109
+9% +$140K
AMAG
103
DELISTED
AMAG Pharmaceuticals
AMAG
$1.7M 0.09%
+75,263
New +$1.8M
WMGI
104
CALL
DELISTED
Wright Medical Group Inc
WMGI
$1.67M 0.09%
+535
New +$14.5K
ACOR
105
DELISTED
Acorda Therapeutics
ACOR
$1.61M 0.09%
638
-1,562
-71% -$4.5M
FOLD
106
PUT
DELISTED
Amicus Therapeutics
FOLD
$1.6M 0.09%
2,241
+1,101
+97% +$6.96K
MDCO
107
CALL
DELISTED
Medicines Co
MDCO
$1.56M 0.08%
320
-137
-30% -$6.25K
SGEN
108
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$1.52M 0.08%
+242
New +$15.1K
SLS icon
109
SELLAS Life Sciences
SLS
$1.99B
$1.5M 0.08%
1,644
+1,628
+10,175% +$2.7M
GBT
110
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.49M 0.08%
+405
New +$10.2K
ARRY
111
DELISTED
Array Biopharma Inc
ARRY
$1.4M 0.08%
+156,074
New +$1.66M
FLXN
112
CALL
DELISTED
Flexion Therapeutics, Inc.
FLXN
$1.39M 0.07%
516
+390
+310% +$7.96K
CDTX
113
DELISTED
Cidara Therapeutics
CDTX
$1.39M 0.07%
8,880
-5,740
-39% -$1.01M
ROKA
114
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$1.37M 0.07%
389,136
+23,916
+7% +$104K
VXZ
115
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$1.31M 0.07%
50,000
– –
ZGNX
116
PUT
DELISTED
Zogenix, Inc.
ZGNX
$1.3M 0.07%
1,201
+1,065
+783% +$10.8K
MRTX
117
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.3M 0.07%
249,735
+150,000
+150% +$822K
BDSI
118
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.28M 0.07%
673,342
-24,893
-4% -$48K
GEVO icon
119
Gevo
GEVO
$353M
$1.27M 0.07%
+57,438
New +$2.43M
ONCS
120
DELISTED
OncoSec Medical Incorporated
ONCS
$1.25M 0.07%
4,436
-900
-17% -$262K
NBSE
121
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.25M 0.07%
3,773
+882
+31% +$409K
OPGN
122
DELISTED
OpGen, Inc
OPGN
$1.24M 0.07%
11
+6
+120% +$674K
XENE icon
123
Xenon Pharmaceuticals
XENE
$6.1B
$1.19M 0.06%
+296,478
New +$2.33M
TRAW icon
124
Traws Pharma
TRAW
$7.34M
$1.17M 0.06%
68
-12
-15% -$186K
INSM icon
125
CALL
Insmed
INSM
$22.4B
$1.16M 0.06%
663
-796
-55% -$12.3K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $725M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 18% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.